Kenvue: Remains A Sell Until The Dividend Is Cut (NYSE:KVUE)

On 22 July 2025, my first analysis about Kenvue ( KVUE ), the former consumer health division of Johnson & Johnson ( JNJ ), was published. I rated the stock a "sell" due to a strong overvaluation as well as expectationsAlways on the hunt for undervalued, promising stocks with a focus on risk and reward. Limited risks and decent to high upside by knowing what one's owning. I strongly believe that the best investment ideas are often the simplest. If contrarian, the better.Analyst’s Disclosure:I/we have no sto ...